JP5021797B2 - トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 - Google Patents
トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 Download PDFInfo
- Publication number
- JP5021797B2 JP5021797B2 JP2010161144A JP2010161144A JP5021797B2 JP 5021797 B2 JP5021797 B2 JP 5021797B2 JP 2010161144 A JP2010161144 A JP 2010161144A JP 2010161144 A JP2010161144 A JP 2010161144A JP 5021797 B2 JP5021797 B2 JP 5021797B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- solvate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PKZLEQIZSZMRRM-UHFFFAOYSA-N CCOC(CNC(c(c1ncn[n]1c(C#Cc1ccccc1)c1)c1OCc1ccccc1)=O)=O Chemical compound CCOC(CNC(c(c1ncn[n]1c(C#Cc1ccccc1)c1)c1OCc1ccccc1)=O)=O PKZLEQIZSZMRRM-UHFFFAOYSA-N 0.000 description 2
- 0 *1*(C=CC=C2)*2=**1 Chemical compound *1*(C=CC=C2)*2=**1 0.000 description 1
- OWBXKJDOUDRGMC-UHFFFAOYSA-N CC(C)(C)OC(CNC(c(c(NN)ncc1-c2ccccc2)c1O)=O)=O Chemical compound CC(C)(C)OC(CNC(c(c(NN)ncc1-c2ccccc2)c1O)=O)=O OWBXKJDOUDRGMC-UHFFFAOYSA-N 0.000 description 1
- WVGNJSIEBDEUBC-UHFFFAOYSA-N CC(C)(C)OC(CNC(c1c(NNC(OC(C)(C)C)=O)ncc(-c2ccccc2)c1O)=O)=O Chemical compound CC(C)(C)OC(CNC(c1c(NNC(OC(C)(C)C)=O)ncc(-c2ccccc2)c1O)=O)=O WVGNJSIEBDEUBC-UHFFFAOYSA-N 0.000 description 1
- YWIROZLWHOKVHD-UHFFFAOYSA-N CC(C)(C)OC(c(c(NN)ncc1)c1OCc1ccccc1)=O Chemical compound CC(C)(C)OC(c(c(NN)ncc1)c1OCc1ccccc1)=O YWIROZLWHOKVHD-UHFFFAOYSA-N 0.000 description 1
- HXGWVFMIUSGMNQ-CCEZHUSRSA-N CC(C)(C)OC(c(c(OCc1ccccc1)cc(/C=C/c1ccccc1)n1)c1Cl)=O Chemical compound CC(C)(C)OC(c(c(OCc1ccccc1)cc(/C=C/c1ccccc1)n1)c1Cl)=O HXGWVFMIUSGMNQ-CCEZHUSRSA-N 0.000 description 1
- WXWKASGKWZPRBT-UHFFFAOYSA-N CC(C)(C)OC(c(c(OCc1ccccc1)cc(Cl)n1)c1Cl)=O Chemical compound CC(C)(C)OC(c(c(OCc1ccccc1)cc(Cl)n1)c1Cl)=O WXWKASGKWZPRBT-UHFFFAOYSA-N 0.000 description 1
- HLGCOFLWTBFGCI-UHFFFAOYSA-N CC(C)(C)OC(c(c(OCc1ccccc1)ccn1)c1Cl)=O Chemical compound CC(C)(C)OC(c(c(OCc1ccccc1)ccn1)c1Cl)=O HLGCOFLWTBFGCI-UHFFFAOYSA-N 0.000 description 1
- RQIRDQNUFIFBKA-IDKOKCKLSA-N CCC(C(O)O)/C(/N[C@@H](C)CCC(CF)C(F)(F)F)=N/C=N Chemical compound CCC(C(O)O)/C(/N[C@@H](C)CCC(CF)C(F)(F)F)=N/C=N RQIRDQNUFIFBKA-IDKOKCKLSA-N 0.000 description 1
- KDXOIDIMSIJKCQ-UHFFFAOYSA-N CCC(CC)c1cc(O)c(C(NCC(O)=O)=O)c2ncn[n]12 Chemical compound CCC(CC)c1cc(O)c(C(NCC(O)=O)=O)c2ncn[n]12 KDXOIDIMSIJKCQ-UHFFFAOYSA-N 0.000 description 1
- JXRAQLOPACADEW-UHFFFAOYSA-N CCOC(CNC(c(c1ncn[n]1c(CCc1ccccc1)c1)c1O)=O)=O Chemical compound CCOC(CNC(c(c1ncn[n]1c(CCc1ccccc1)c1)c1O)=O)=O JXRAQLOPACADEW-UHFFFAOYSA-N 0.000 description 1
- QDJOCGSSILQCET-UHFFFAOYSA-N CCOC(c([n]1ncnc1c(C#CC(C)(C)C)c1)c1OCc1ccccc1)=O Chemical compound CCOC(c([n]1ncnc1c(C#CC(C)(C)C)c1)c1OCc1ccccc1)=O QDJOCGSSILQCET-UHFFFAOYSA-N 0.000 description 1
- LPNOCLSPTIDNOR-UHFFFAOYSA-N CCOC(c([n]1ncnc1c(CCC(C)(C)C)c1)c1O)=O Chemical compound CCOC(c([n]1ncnc1c(CCC(C)(C)C)c1)c1O)=O LPNOCLSPTIDNOR-UHFFFAOYSA-N 0.000 description 1
- CWCNCKDAWRQFGE-BUHFOSPRSA-N CCOC(c(c1ncn[n]1cc1/C=C/c2ccccc2)c1OCc1ccccc1)=O Chemical compound CCOC(c(c1ncn[n]1cc1/C=C/c2ccccc2)c1OCc1ccccc1)=O CWCNCKDAWRQFGE-BUHFOSPRSA-N 0.000 description 1
- INLJCWZKSRRTDW-UHFFFAOYSA-N CCOC(c(c1ncn[n]1cc1CCc2ccccc2)c1O)=O Chemical compound CCOC(c(c1ncn[n]1cc1CCc2ccccc2)c1O)=O INLJCWZKSRRTDW-UHFFFAOYSA-N 0.000 description 1
- MFPUMTORXOJKQN-UHFFFAOYSA-N Cc1cc(-c2cc(O)c(C(NCC(O)=O)=O)c3ncn[n]23)cc(F)c1 Chemical compound Cc1cc(-c2cc(O)c(C(NCC(O)=O)=O)c3ncn[n]23)cc(F)c1 MFPUMTORXOJKQN-UHFFFAOYSA-N 0.000 description 1
- HCPQBNNCIMQKLM-UHFFFAOYSA-N Cc1ccc(C)[n]1-c(ncc(OCc1ccccc1)c1)c1Br Chemical compound Cc1ccc(C)[n]1-c(ncc(OCc1ccccc1)c1)c1Br HCPQBNNCIMQKLM-UHFFFAOYSA-N 0.000 description 1
- FETOEVKYTOUGGQ-UHFFFAOYSA-N Nc(c(Br)c1)ncc1OCc1ccccc1 Chemical compound Nc(c(Br)c1)ncc1OCc1ccccc1 FETOEVKYTOUGGQ-UHFFFAOYSA-N 0.000 description 1
- PBWWQUYNVHEZCF-UHFFFAOYSA-N OC(CNC(c(c1ncn[n]1c(CCC1CC1)c1)c1O)=O)=O Chemical compound OC(CNC(c(c1ncn[n]1c(CCC1CC1)c1)c1O)=O)=O PBWWQUYNVHEZCF-UHFFFAOYSA-N 0.000 description 1
- UZQSBUBOPYNNMP-UHFFFAOYSA-N OC(CNC(c(c1ncn[n]1c(CCC1CCCC1)c1)c1O)=O)=O Chemical compound OC(CNC(c(c1ncn[n]1c(CCC1CCCC1)c1)c1O)=O)=O UZQSBUBOPYNNMP-UHFFFAOYSA-N 0.000 description 1
- GKNIAAODWUWQIY-UHFFFAOYSA-N OC(c(c1ncn[n]1c(C#Cc1ccccc1)c1)c1OCc1ccccc1)=O Chemical compound OC(c(c1ncn[n]1c(C#Cc1ccccc1)c1)c1OCc1ccccc1)=O GKNIAAODWUWQIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010161144A JP5021797B2 (ja) | 2009-07-17 | 2010-07-16 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009169565 | 2009-07-17 | ||
| JP2009169565 | 2009-07-17 | ||
| JP2010161144A JP5021797B2 (ja) | 2009-07-17 | 2010-07-16 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012101381A Division JP2012144571A (ja) | 2009-07-17 | 2012-04-26 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011037841A JP2011037841A (ja) | 2011-02-24 |
| JP2011037841A5 JP2011037841A5 (enExample) | 2012-03-08 |
| JP5021797B2 true JP5021797B2 (ja) | 2012-09-12 |
Family
ID=43449466
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010161144A Active JP5021797B2 (ja) | 2009-07-17 | 2010-07-16 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2012101381A Ceased JP2012144571A (ja) | 2009-07-17 | 2012-04-26 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2014207896A Pending JP2015003933A (ja) | 2009-07-17 | 2014-10-09 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2015239065A Pending JP2016040321A (ja) | 2009-07-17 | 2015-12-08 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2017134270A Expired - Fee Related JP6434575B2 (ja) | 2009-07-17 | 2017-07-10 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2018210486A Pending JP2019019144A (ja) | 2009-07-17 | 2018-11-08 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2020074508A Ceased JP2020111612A (ja) | 2009-07-17 | 2020-04-20 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2022104161A Ceased JP2022126843A (ja) | 2009-07-17 | 2022-06-29 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2024070200A Pending JP2024091878A (ja) | 2009-07-17 | 2024-04-24 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012101381A Ceased JP2012144571A (ja) | 2009-07-17 | 2012-04-26 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2014207896A Pending JP2015003933A (ja) | 2009-07-17 | 2014-10-09 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2015239065A Pending JP2016040321A (ja) | 2009-07-17 | 2015-12-08 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2017134270A Expired - Fee Related JP6434575B2 (ja) | 2009-07-17 | 2017-07-10 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2018210486A Pending JP2019019144A (ja) | 2009-07-17 | 2018-11-08 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2020074508A Ceased JP2020111612A (ja) | 2009-07-17 | 2020-04-20 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2022104161A Ceased JP2022126843A (ja) | 2009-07-17 | 2022-06-29 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2024070200A Pending JP2024091878A (ja) | 2009-07-17 | 2024-04-24 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8283465B2 (enExample) |
| EP (3) | EP2455381B9 (enExample) |
| JP (9) | JP5021797B2 (enExample) |
| KR (4) | KR101706803B1 (enExample) |
| CN (1) | CN102471337B (enExample) |
| AR (1) | AR077417A1 (enExample) |
| AU (1) | AU2010271732B2 (enExample) |
| BR (1) | BR112012001157A2 (enExample) |
| CA (1) | CA2768505C (enExample) |
| CO (1) | CO6430426A2 (enExample) |
| DK (1) | DK2455381T5 (enExample) |
| ES (1) | ES2477968T3 (enExample) |
| HR (1) | HRP20140705T1 (enExample) |
| IL (1) | IL217541A (enExample) |
| ME (1) | ME01858B (enExample) |
| MX (1) | MX2012000766A (enExample) |
| MY (1) | MY160814A (enExample) |
| NZ (1) | NZ598242A (enExample) |
| PE (1) | PE20120629A1 (enExample) |
| PL (1) | PL2455381T3 (enExample) |
| PT (1) | PT2455381E (enExample) |
| RS (1) | RS53499B1 (enExample) |
| RU (1) | RU2538963C2 (enExample) |
| SG (1) | SG178049A1 (enExample) |
| SI (1) | SI2455381T1 (enExample) |
| SM (1) | SMT201500122B (enExample) |
| TW (1) | TWI485150B (enExample) |
| WO (1) | WO2011007856A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012144571A (ja) * | 2009-07-17 | 2012-08-02 | Japan Tobacco Inc | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011168582A (ja) * | 2010-01-21 | 2011-09-01 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤 |
| WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| CN104936591B (zh) | 2012-11-26 | 2018-05-29 | 国立大学法人东北大学 | 促红细胞生成素表达增强剂 |
| AU2013368843B2 (en) | 2012-12-24 | 2016-02-25 | Zydus Lifesciences Limited | Novel quinolone derivatives |
| PE20160194A1 (es) | 2013-06-13 | 2016-04-20 | Akebia Therapeutics Inc | Composiciones y metodos para tratar anemia |
| RU2534804C1 (ru) * | 2013-08-05 | 2014-12-10 | Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") | ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ |
| ME02991B (me) * | 2013-10-03 | 2018-10-20 | Kura Oncology Inc | Ekr inhibitori i postupci primene |
| WO2016034108A1 (zh) | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| JP2018039733A (ja) * | 2014-12-22 | 2018-03-15 | 株式会社富士薬品 | 新規複素環誘導体 |
| GB201504565D0 (en) * | 2015-03-18 | 2015-05-06 | Takeda Pharmaceutical | Novel compounds |
| CN106146395B (zh) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| JP6814134B2 (ja) * | 2015-05-28 | 2021-01-13 | 日本たばこ産業株式会社 | 糖尿病性腎症を治療又は予防する方法 |
| WO2018097254A1 (ja) | 2016-11-25 | 2018-05-31 | 日本たばこ産業株式会社 | トリアゾロピリジン化合物の製造方法 |
| CA3062972C (en) | 2017-05-09 | 2021-09-14 | Kind Pharmaceutical | Indolizine derivatives and their application in medicine |
| PE20200846A1 (es) * | 2017-10-04 | 2020-08-18 | Japan Tobacco Inc | Compuesto de heteroarilo con contenido de nitrogeno y su uso farmaceutico |
| CN107739378A (zh) * | 2017-11-14 | 2018-02-27 | 杭州安道药业有限公司 | 吲哚嗪衍生物及其在医药上的应用 |
| BR112021004730A2 (pt) | 2018-09-13 | 2021-06-01 | Kissei Pharmaceutical Co., Ltd. | composto de imidazopiridinona |
| CN110105355B (zh) * | 2019-05-24 | 2021-09-21 | 烟台大学 | 一种1,2,3-三唑-[1,5-a]并喹啉类化合物的制备方法 |
| US20230167108A1 (en) * | 2020-03-11 | 2023-06-01 | Kissei Pharmaceutical Co., Ltd. | Crystal of imidazopyridinone compound or salt thereof |
| JP7504822B2 (ja) * | 2020-03-12 | 2024-06-24 | キッセイ薬品工業株式会社 | イミダゾピリジノン化合物を含む医薬組成物 |
| EP4138825A1 (en) | 2020-04-20 | 2023-03-01 | Akebia Therapeutics Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| CN113387948B (zh) * | 2021-02-06 | 2022-06-10 | 成都诺和晟泰生物科技有限公司 | 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途 |
| TW202313072A (zh) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
| CN113582843A (zh) * | 2021-09-09 | 2021-11-02 | 无锡捷化医药科技有限公司 | 一种5-氯-2-氟-3-羟基苯甲酸乙酯的制备方法 |
| CN116496269B (zh) * | 2021-12-02 | 2025-02-28 | 苏中药业集团股份有限公司 | 一种脯氨酰羟化酶抑制剂及其用途 |
| CN114031619A (zh) * | 2021-12-17 | 2022-02-11 | 山东汇海医药化工有限公司 | 一种图卡替尼中间体的制备方法 |
| WO2024061172A1 (zh) * | 2022-09-19 | 2024-03-28 | 苏中药业集团股份有限公司 | 一种脯氨酰羟化酶抑制剂及其用途 |
| WO2024245389A1 (zh) * | 2023-06-02 | 2024-12-05 | 苏中药业集团股份有限公司 | 一种脯氨酰羟化酶抑制剂及其用途 |
| TW202506675A (zh) * | 2023-08-08 | 2025-02-16 | 美商富曼西公司 | 用於防治和對抗無脊椎有害生物的連接的雙環化合物 |
| CN117486878A (zh) * | 2023-10-27 | 2024-02-02 | 扬州市普林斯医药科技有限公司 | 一种恩那司他的制备方法 |
| WO2025137158A1 (en) * | 2023-12-19 | 2025-06-26 | Akebia Therapeutics, Inc. | Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use |
| WO2025167738A1 (zh) * | 2024-02-05 | 2025-08-14 | 深圳信立泰药业股份有限公司 | 化合物在制备治疗非髓系恶性肿瘤患者的贫血药物中的应用 |
| WO2025167739A1 (zh) * | 2024-02-05 | 2025-08-14 | 深圳信立泰药业股份有限公司 | 化合物在制备预防和/或治疗高原病的药物中的应用 |
| CN119039291A (zh) * | 2024-09-09 | 2024-11-29 | 南京药坦生物科技有限公司 | 一种恩那度司他中间体及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| WO2003030904A1 (en) * | 2001-10-08 | 2003-04-17 | F. Hoffmann-La Roche Ag | 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide |
| CN1832920A (zh) | 2003-08-08 | 2006-09-13 | 特兰斯泰克制药公司 | 芳基和杂芳基化合物,组合物及其使用方法 |
| CN1993323B (zh) * | 2004-08-05 | 2011-04-20 | 霍夫曼-拉罗奇有限公司 | 吲哚，吲唑或二氢吲哚衍生物 |
| FR2889383A1 (fr) * | 2005-08-01 | 2007-02-02 | France Telecom | Procede et dispositif de detection pour systeme mimo, systeme mimo, programme et support d'information |
| AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| WO2007136990A2 (en) | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| AR061570A1 (es) | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| PL3357911T3 (pl) * | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
| US20100035756A1 (en) | 2006-07-12 | 2010-02-11 | Syngenta Limited | Triazolophyridine derivatives as herbicides |
| CL2008000066A1 (es) * | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| ES2442847T3 (es) | 2007-04-18 | 2014-02-13 | Amgen, Inc | Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa |
| AU2008248165B2 (en) | 2007-05-04 | 2011-12-08 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| WO2009005076A1 (ja) | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
| AU2008329746A1 (en) * | 2007-11-30 | 2009-06-04 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| JP2011508725A (ja) * | 2007-11-30 | 2011-03-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| US8324241B2 (en) * | 2008-04-11 | 2012-12-04 | Bristol-Myers Squibb Company | Triazolo compounds useful as DGAT1 inhibitors |
| US20110039895A1 (en) | 2008-04-30 | 2011-02-17 | Glaxo Smith Kline LLC., a corporation | Prolyl hydroxylase inhibitors |
| JP2011521960A (ja) | 2008-05-29 | 2011-07-28 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュイン調節薬としてのイミダゾピリジンおよび関連する類似体 |
| HRP20160488T1 (hr) | 2008-12-19 | 2016-06-17 | Leo Pharma A/S | Triazolopiridini kao inhibitori fosfodiesteraze za liječenje kožnih bolesti |
| DK2455381T5 (en) * | 2009-07-17 | 2015-02-09 | Japan Tobacco Inc | Triazolopyridinforbindelse and its effect as an inhibitor of prolyl hydroxylase and induce erythropoietin production by |
-
2010
- 2010-07-16 DK DK10799914.6T patent/DK2455381T5/en active
- 2010-07-16 MX MX2012000766A patent/MX2012000766A/es active IP Right Grant
- 2010-07-16 AR ARP100102614A patent/AR077417A1/es active IP Right Grant
- 2010-07-16 US US12/837,679 patent/US8283465B2/en active Active
- 2010-07-16 EP EP10799914.6A patent/EP2455381B9/en active Active
- 2010-07-16 SG SG2012003570A patent/SG178049A1/en unknown
- 2010-07-16 PL PL10799914T patent/PL2455381T3/pl unknown
- 2010-07-16 HR HRP20140705AT patent/HRP20140705T1/hr unknown
- 2010-07-16 NZ NZ598242A patent/NZ598242A/xx unknown
- 2010-07-16 CN CN201080032238.2A patent/CN102471337B/zh active Active
- 2010-07-16 CA CA2768505A patent/CA2768505C/en active Active
- 2010-07-16 AU AU2010271732A patent/AU2010271732B2/en active Active
- 2010-07-16 PE PE2012000056A patent/PE20120629A1/es active IP Right Grant
- 2010-07-16 BR BR112012001157A patent/BR112012001157A2/pt not_active Application Discontinuation
- 2010-07-16 EP EP19188636.5A patent/EP3594213A1/en not_active Withdrawn
- 2010-07-16 RS RSP20140406 patent/RS53499B1/sr unknown
- 2010-07-16 MY MYPI2012000223A patent/MY160814A/en unknown
- 2010-07-16 KR KR1020127004258A patent/KR101706803B1/ko active Active
- 2010-07-16 SI SI201030682T patent/SI2455381T1/sl unknown
- 2010-07-16 TW TW099123410A patent/TWI485150B/zh active
- 2010-07-16 KR KR1020177003353A patent/KR101850661B1/ko active Active
- 2010-07-16 RU RU2012105467/04A patent/RU2538963C2/ru active
- 2010-07-16 KR KR1020187010331A patent/KR20180042443A/ko not_active Ceased
- 2010-07-16 WO PCT/JP2010/062037 patent/WO2011007856A1/ja not_active Ceased
- 2010-07-16 KR KR1020237040564A patent/KR20230165366A/ko not_active Ceased
- 2010-07-16 EP EP14160395.1A patent/EP2746282A1/en not_active Withdrawn
- 2010-07-16 JP JP2010161144A patent/JP5021797B2/ja active Active
- 2010-07-16 ME MEP-2014-82A patent/ME01858B/me unknown
- 2010-07-16 PT PT107999146T patent/PT2455381E/pt unknown
- 2010-07-16 ES ES10799914.6T patent/ES2477968T3/es active Active
-
2012
- 2012-01-15 IL IL217541A patent/IL217541A/en active IP Right Grant
- 2012-01-31 CO CO12014916A patent/CO6430426A2/es active IP Right Grant
- 2012-04-26 JP JP2012101381A patent/JP2012144571A/ja not_active Ceased
- 2012-09-06 US US13/605,329 patent/US20130096155A1/en not_active Abandoned
-
2014
- 2014-10-09 JP JP2014207896A patent/JP2015003933A/ja active Pending
-
2015
- 2015-05-22 SM SM201500122T patent/SMT201500122B/xx unknown
- 2015-06-25 US US14/749,966 patent/US20160145254A1/en not_active Abandoned
- 2015-12-08 JP JP2015239065A patent/JP2016040321A/ja active Pending
-
2017
- 2017-07-10 JP JP2017134270A patent/JP6434575B2/ja not_active Expired - Fee Related
-
2018
- 2018-11-08 JP JP2018210486A patent/JP2019019144A/ja active Pending
-
2020
- 2020-04-20 JP JP2020074508A patent/JP2020111612A/ja not_active Ceased
-
2022
- 2022-06-29 JP JP2022104161A patent/JP2022126843A/ja not_active Ceased
-
2024
- 2024-04-24 JP JP2024070200A patent/JP2024091878A/ja active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012144571A (ja) * | 2009-07-17 | 2012-08-02 | Japan Tobacco Inc | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2015003933A (ja) * | 2009-07-17 | 2015-01-08 | 日本たばこ産業株式会社 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2016040321A (ja) * | 2009-07-17 | 2016-03-24 | 日本たばこ産業株式会社 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2017214404A (ja) * | 2009-07-17 | 2017-12-07 | 日本たばこ産業株式会社 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2019019144A (ja) * | 2009-07-17 | 2019-02-07 | 日本たばこ産業株式会社 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
| JP2020111612A (ja) * | 2009-07-17 | 2020-07-27 | 日本たばこ産業株式会社 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6434575B2 (ja) | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 | |
| KR102680164B1 (ko) | Rock 억제제로서의 페닐아세트아미드 | |
| CN104884454B (zh) | 用作IL‑12、IL‑23和/或IFNα应答调节剂的酰胺取代的杂环化合物 | |
| US20200017492A1 (en) | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent | |
| AU2012240026A1 (en) | Methods and compositions for treating neurodegenerative diseases | |
| EP3741752A1 (en) | Tam family kinase /and csf1r kinase inhibitor and use thereof | |
| KR20210048589A (ko) | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 | |
| HK1168346B (en) | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer | |
| HK40041650A (en) | Tam family kinase /and csf1r kinase inhibitor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120125 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120125 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20120125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120126 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20120222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120306 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120426 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120605 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120614 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5021797 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150622 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |